Abbvie Biotherapeutics Inc.

Facet Biotech Corporation

Abbott Biotherapeutics Corp.

Pdl Biopharma, Inc.

David Powers

Vanitha Ramakrishnan

Vinay Bhaskar

Dale E Johnson

Ursula Jeffry

Robert B Dubridge

J Yun Tso

Daniel E Afar

Nicholas F Landolfi

Ingrid W Caras

Gao Liu

Marna Williams

Debbie Law

Yoshiko Akamatsu

Richard Murray

Agustin De La Calle

Fiona A Harding

Charles M Forsyth

Patricia Culp

Ping Y Huang

Shiming Ye

Alan F Wahl

Ingrid Caras

The present disclosure provides bispecific proteins that bind to two antigens, as well as their compositions, uses, and methods of making.

Bispecific binding proteins that bind CD40 and mesothelin

The present disclosure relates to antibodies directed to the tumor necrosis factor alpha ('TNF-&#x3b1;') and uses of such antibodies, for example, to treat diseases associated with the activity and/or overproduction of TNF-&#x3b1;.

Anti-TNF-alpha antibodies and their uses

The present disclosure relates to antibodies directed to vascular endothelial growth factor ('VEGF') and uses of such antibodies, for example to treat diseases associated with the activity and/or overproduction of VEGF.

Anti-VEGF antibodies and their uses

The present disclosure relates to antibodies directed to HER2 and uses of such antibodies, for example to treat diseases associated with the activity and/or overproduction of HER2.

Anti-HER2 antibodies and their uses

Anti-TNF-&#x3b1; antibodies and their uses

The present invention relates to antibodies directed to EGFR and uses of such antibodies, for example, to treat diseases associated with the activity and/or overproduction of EGFR.

Anti-EGFR antibodies and their uses

The invention provides methods of making designed and constructed protein (e.g., antibody) libraries and libraries resulting from the same.

Methods of screening complex protein libraries to identify altered properties

The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists.

Therapeutic use of anti-CS1 antibodies

The present invention provides chimeric and humanized antibodies that specifically recognize &#x3b1;5&#x3b2;1 integrin, and methods for using the antibodies for reducing or inhibiting angiogenesis in a tissue. Also provided are methods of determining therapeutically acceptable doses of the antibodies and pharmaceutical compositions including the same.

Chimeric and humanized antibodies to &#x3b1;5&#x3b2;1 integrin that modulate angiogenesis

The invention relates to the identification and generation of antibodies that bind to TMEFF2 proteins which are involved in cancer. Further, the invention provides for the use of these antibodies in the treatment of cancer.

Antibodies against cancer antigen TMEFF2 and uses thereof

Growing community of inventors

Fairfax, CA, United States of America

David Powers